Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)

• ClinicalTrials.gov Identifier: NCT05814666
• Recruitment Status: Recruiting
• First Posted: April 18, 2023
• Last Update Posted: April 10, 2024
• Sponsor: Flamingo Therapeutics NV
• Information provided by (Responsible Party): Flamingo Therapeutics NV

Tracking Information

• First Submitted Date: March 10, 2023
• First Posted Date: April 18, 2023
• Last Update Posted Date: April 10, 2024
• Actual Study Start Date: May 30, 2023
• Estimated Primary Completion Date: May 30, 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 3, 2023)

Confirmed ORR [ Time Frame: Up to 18 months ]

Determine the ORR (Partial response [PR] + CR defined according to RECIST v1.1) as determined by the Investigator for the combination of danvatirsen and pembrolizumab compared with pembrolizumab alone

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: April 8, 2024)

• Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to 18 months ]
  Drug induced toxicities are assessed and graded according to Common Toxicity Criteria for Adverse Events (CTCAE) Version 5.0.
• DOR [ Time Frame: Up to 18months ]
  Duration of Response by RECIST v1.1
• DCR & CR Rate [ Time Frame: Up to 18months ]
  Disease control rate and complete response rate by RECIST v1.1
• ORR in tumors with CPS ≥50 [ Time Frame: Up to 18months ]
  Overall response rate per RECIST v1.1 in tumors with CPS ≥ 20 and ≥ 50
• DOR in tumors with CPS ≥50 [ Time Frame: Up to 18months ]
  Duration of response by RECIST v1.1 in tumors with CPS ≥50
• PFS [ Time Frame: Up to 18months ]
  Progression-free survival by RECIST v1.1, defined as the time from randomization to the first documentation of progressive disease (PD) or death from any cause, whichever comes first
• OS [ Time Frame: Up to 30months ]
  Overall survival, defined as time from randomization to death from any cause
• Maximum plasma concentration [ Time Frame: Up to 18 months ]
  Maximum concentration recorded [Cmax]of danvatirsen at defined timepoints in the combination regimen
• Trough concentration [ Time Frame: Up to 18 months ]
  Trough concentration [Ctrough] of danvatirsen at defined timepoints in the combination regimen
• Area under the plasma concentration-time curve [ Time Frame: Up to 18 months ]
  Area under the plasma concentration-time curve over the dosing interval [AUCtau] of danvatirsen at defined timepoints in the combination regimen
• Time to maximum plasma concentration [ Time Frame: Up to 18 months ]
  Time to maximum plasma concentration [Tmax]) after single and multiple doses at defined timepoints in the combination regimen
• Immunogenicity of danvatirsen [ Time Frame: Up to 18 months ]
  Anti-danvatirsen antibody titers at defined timepoints in the combination regimen

Original Secondary Outcome Measures (submitted: April 3, 2023)

• Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Up to 18 months ]
  Drug induced toxicities are assessed and graded according to Common Toxicity Criteria for Adverse Events (CTCAE) Version 5.0.
• DOR [ Time Frame: Up to 18months ]
  Duration of Response by RECIST v1.1
• DCR & CR Rate [ Time Frame: Up to 18months ]
  Disease control rate and complete response rate by RECIST v1.1
• ORR in tumors with CPS ≥50 [ Time Frame: Up to 18months ]
  Overall response rate per RECIST v1.1 in tumors with CPS ≥50
• DOR in tumors with CPS ≥50 [ Time Frame: Up to 18months ]
  Duration of response by RECIST v1.1 in tumors with CPS ≥50
• PFS [ Time Frame: Up to 18months ]
  Progression-free survival by RECIST v1.1, defined as the time from randomization to the first documentation of progressive disease (PD) or death from any cause, whichever comes first
• OS [ Time Frame: Up to 30months ]
  Overall survival, defined as time from randomization to death from any cause
• Maximum plasma concentration [ Time Frame: Up to 18 months ]
  Maximum concentration recorded [Cmax]of danvatirsen at defined timepoints in the combination regimen
• Trough concentration [ Time Frame: Up to 18 months ]
  Trough concentration [Ctrough] of danvatirsen at defined timepoints in the combination regimen
• Area under the plasma concentration-time curve [ Time Frame: Up to 18 months ]
  Area under the plasma concentration-time curve over the dosing interval [AUCtau] of danvatirsen at defined timepoints in the combination regimen
• Time to maximum plasma concentration [ Time Frame: Up to 18 months ]
  Time to maximum plasma concentration [Tmax]) after single and multiple doses at defined timepoints in the combination regimen
• Immunogenicity of danvatirsen [ Time Frame: Up to 18 months ]
  Anti-danvatirsen antibody titers at defined timepoints in the combination regimen

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
• Official Title: An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
• Brief Summary: Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.

Detailed Description

This is a multicenter, open-label, Phase II, randomized, controlled study to determine the efficacy, safety, and other indicators of clinical and biological activity of the combination of danvatirsen and pembrolizumab as first-line treatment for R/M HNSCC.

After providing informed consent, patients will be assessed for eligibility during the screening phase of the study. All patients must be willing and able to provide a formalin fixed paraffin-embedded (FFPE) archival or fresh tumor sample collected during the screening period; a fresh biopsy is preferred if safe and feasible to obtain and consented to by the patient. Following the screening period, eligible patients will be randomized in a 2:1 ratio to danvatirsen + pembrolizumab or pembrolizumab monotherapy, respectively. Patients will receive treatment in 21-day cycles. Patients assigned to the pembrolizumab monotherapy arm will receive treatment until a criterion for discontinuation is met or a maximum of 24 months of treatment. Patients assigned to combination therapy will receive both treatments until a criterion for discontinuation is met or the patient has received a maximum of 24 months of treatment, after which they may remain on danvatirsen monotherapy.

Patients in both treatment arms will have radiologic tumor assessments every 6 weeks (±1 week), regardless of treatment delays, until objective disease progression, initiation of new anticancer treatment, death, withdrawal of consent, or end of study, whichever occurs first.

All patients who discontinue study treatment for any reason will have a safety follow-up visit 30 days (+7 days) after the last dose of study treatment and a follow-up for AEs 90 days (+7 days) after the last dose of pembrolizumab. Patients will be followed for survival at 12 week (±7 days) intervals until death or withdrawal of consent, whichever occurs first. Survival follow-up will continue until at least 15 months after the last patient is randomized in the study.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: HNSCC

Intervention

• Drug: Danvatirsen
  Danvatirsen is a STAT3 targeting drug.
  Other Names:

  • ISIS 481464
  • AZD9150
• Drug: Pembrolizumab
  Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
  Other Name: Keytruda

Study Arms

• Experimental: Danvatirsen plus pembrolizumab

  Danvatirsen dosing:

  Week 1: Danvatirsen intravenously (IV) on Days 1, 3, and 5

  Week 2 and subsequent weeks: Danvatirsen IV weekly

  Pembrolizumab dosing:

  Pembrolizumab every 3 weeks after the Danvatirsen dose.

  Interventions:

  • Drug: Danvatirsen
  • Drug: Pembrolizumab
• Active Comparator: Pembrolizumab
  Pembrolizumab IV every 3 weeks after the Danvatirsen dose.
  Intervention: Drug: Pembrolizumab

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: April 3, 2023): 81
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: May 30, 2026
• Estimated Primary Completion Date: May 30, 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Must have given written informed consent (signed and dated).
2. Aged ≥18 years at the time of informed consent.
3. Recurrent/metastatic histologically or cytologically proven squamous cell carcinoma of the head and neck that is considered incurable by local therapy. Eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
4. Presence of measurable tumor per RECIST v1.1 criteria.
5. Detectable PD-L1 expression in tumor, defined as CPS ≥1 determined by a FDA or national regulatory agency of the country in which the patient resides.-approved test.
6. Baseline fresh tumor biopsy or archival specimen.
7. ECOG performance status of 0 or 1.
8. Adequate organ function within 10 days of study treatment,
9. Oxygen saturation on room air ≥92% by pulse oximetry.
10. Females must be non-pregnant and non-lactating and either be postmenopausal or agree to adequate birth control.
11. Males must be surgically sterile or agree to adequate birth control.
12. Has an estimated life expectancy of at least 3 months.
13. Has recovered from all complications or surgery and all toxicities of prior therapy

Exclusion Criteria:

1. Prior therapy for metastatic HNSCC.
2. Has disease suitable for local therapy with curative intent.
3. Primary tumor of the nasopharynx.
4. Has received prior therapy with an anti-programmed death 1 (PD-1), anti PD L1, or anti-programmed death-ligand-2 (PD-L2).
5. Radiation therapy (or other non-systemic therapy) within 2 weeks of Day 1 of study treatment.
6. Known autoimmune disease that has required systemic treatment
7. Known immunodeficiency or receiving systemic steroid therapy that would be the equivalent of >10 mg prednisone daily
8. Prior allogeneic tissue/solid organ transplant.
9. Has significant cardiovascular disease
10. Has received a live vaccine within 30 days
11. Active infection requiring systemic antiviral or antimicrobial therapy
12. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
13. History of other malignancies
14. Active HIV infection except patients who are currently stable on antiretroviral therapy for at least 4 weeks
15. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
16. Treated or untreated parenchymal brain metastases or leptomeningeal disease.
17. Treatment with another investigational drug, biological agent, or device within 1 month of screening, or 5 half-lives of investigational agent (if known), whichever is longer.
18. Hypersensitivity to any component of danvatirsen or pembrolizumab.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Flamingo Therapeutics; +1 484 482 0007; clinical@flamingotx.com

• Listed Location Countries: Korea, Republic of, United States

Administrative Information

• NCT Number: NCT05814666
• Other Study ID Numbers: FLM-6774-201
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Flamingo Therapeutics NV
• Original Responsible Party: Same as current
• Current Study Sponsor: Flamingo Therapeutics NV
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Flamingo Therapeutics NV
• Verification Date: April 2024